R01CA269948

Generalizable Quantitative Imaging and Machine Learning Signatures in Glioblastoma, for Precision Diagnostics and Personalized Treatment: The RESPOND Consortium - Abstract

The current state of magnetic resonance imaging (MRI) methods in neurooncology offers great potential for providing rich characterizations of structural, physiological, and metabolic characteristics of brain tumors, especially gliomas, which are complex and highly heterogeneous cancers.

Glioblastoma (GBM), in particular, has a grim prognosis, with median overall survival (OS) less than 15 months with relatively little improvement in the past 15 years since the Stupp protocol was introduced. Many experimental treatments are being pursued; however, OS has largely remained stagnant.

Some of the obstacles in improving this outcome have been:

1) Disease heterogeneity, which both renders it difficult to detect treatment effects in phase 1 or even phase 2 trials, and calls for personalized, rather than one-size-fits-all, treatment strategies.

2) Methods used for tumor characterization based on size, enhancement, perfusion, and diffusion properties are relatively crude and don't fully leverage the richness of imaging data or their spatial heterogeneity.

Quantitative imaging and machine learning (QIML) methods developed in the past decade have shown great potential for dissecting the spatial, temporal, and inter-patient heterogeneity of GBM; for discovering relationships between imaging and molecular characteristics; for offering personalized predictions of clinical outcome; and for leveraging subtle multi-parametric relationships in the data to detect peri-tumoral infiltration or distinguish treatment-related changes, i.e., pseudo-progression (PSP), from true tumor recurrence.

Our group has been at the forefront of QIML, with emphasis on:

a) Obtaining rich imaging phenotypes relying on multi-parametric signals, texture parameters, shape properties, spatial patterns derived from atlas registration, and biophysical models of tumor growth.

b) Integrating such imaging signatures using machine learning into predictors of clinical outcome, early recurrence from peri-tumoral infiltration, PSP, and radiologic subtypes of GBM.

Despite their promise, QIML methods have a notorious limitation: they might overfit specific datasets from which they are derived and might display poor reproducibility under real-life conditions of variable scanner types and imaging protocols.

In this proposal, we aim to leverage the recently formed RESPOND (Radiomics Signatures for Precision Diagnostics) Consortium to integrate, harmonize, and analyze 4,578 datasets from 14 centers around the world and hence more appropriately train and cross-validate QIML tools for a wider generalizability.

This consortium will generate an unprecedented database of diverse and carefully harmonized sets of MRI and clinical measures and aims to provide the community with robust and reproducible QIML models contributing to precision diagnostics and personalized treatment for this dreaded brain cancer.

Trustees Of The University Of Pennsylvania

NOT APPLICABLE

93.394 - Cancer Detection and Diagnosis Research

National Cancer Institute (NCI) [HHS - NIH]

Philadelphia, Pennsylvania 191046116 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 325% from $764,489 to $3,249,567.